EXEL – EXELIXIS – new all time highs today for the molecule therapy drug developer.

EXEL – EXELIXIS – a difficult stock to pronounce correctly, but despite that it’s new all time highs today for the molecule therapy drug developer.

This biotech has seen the last 4 quarters with close to 500% growth in sales, a key characteristic in big winning stocks.

Here’s the weekly chart for the biotech recent IPO:

EXEL - Exelixis Weekly Chart
Copper-futures-analysis